
Sorrento: Limited Potential, High Management Compensation, Complicated Lawsuits (SRNE)
Pgiam/iStock via Getty Images Sorrento Therapeutics (NASDAQ:SRNE) is a commercial-stage company that, I would say, made a more or less failed effort to play the Covid-19 R&D surge, but has now gone back to doing […]